Commission Report Highlights the Potential of Personalised Medicine

The European Commission has published a report which takes stock of the progress made in the field of personalised medicine and the opportunities and challenges associated with its implementation in a healthcare setting. The report focuses on three main areas: 1) the potential for, and issues with, the use of '-omics' technologies in personalised medicine, and the related EU research funding, 2) recent developments in EU legislation for placing medicinal products and devices on the market, and 3) factors affecting the uptake of personalised medicine in health care systems.

The report concludes that personalised medicine has the potential to offer new treatment opportunities for the benefit of patients, including better targeted treatment, avoiding medical errors and reducing adverse reactions to medicines.

Personalised Medicine should be seen as an evolution of medicine, rather than a revolution, and the report recognises the challenges (e.g. in research) associated with its successful entry in healthcare systems. The European Commission will continue to monitor the developments of personalised medicine in the coming years and maintain a fruitful dialogue with stakeholders.

What is personalised medicine?
Although no official definition of personalised medicine exists, it can best be explained as a medical approach which is tailored to the patient or a group of pati! ents - for prevention, prediction and treatment. In other words, it moves away from the common "one size fits all" medical model.

How does the EU support personalised medicine?
Since 2007 the EU has committed over €1 billion of health research funding underpinning the development of personalised medicine through its Seventh Framework Program for Research and Technological Innovation. Going forward, funding under Horizon 2020, the EU's new framework program to be launched at the end of this year, will continue to support this field.

A constructive legal framework has also contributed to the development of personalised medicine. The regulatory framework for pharmaceuticals offers a number of tools and procedures to ensure that medicines placed on the market are of high quality, safety and efficacy. These tools, complemented by scientific guidelines and expert evaluation, have already worked well for innovative products including therapies relevant to personalised medicine.

The ongoing revisions of important pieces of legislation address certain challenges identified in the development of these therapies. The revision of the medical devices legislation will strengthen the legal framework of in vitro diagnostics and introduce a better consultation process for companion diagnostics to assess patient eligibility for treatment with a specific medicinal product. The revision of the Clinical Trials Directive is expected to simplify the conduct of clinical trials and consequently facilitate research in therapies using personalised medicine.

Finally, EU-level cooperation on Health Technology Assessment can help Member States assess the value of using personalised medicine in their health systems, i.e. judge whether their benefits will offset their costs through efficiency gains.

Download: Use of '-omics' technologies in the development of personalised medicine (.pdf, 258 KB).

Download from eHealthNews.eu Portal's mirror: Use of '-omics' technologies in the development of personalised medicine (.pdf, 258 KB).

Most Popular Now

Senior Nurse adds to Clinical Expertise …

A senior nurse with more than 20 years' experience in the NHS has joined smart health tech provider Alcidion in a core role as a clinical consultant primarily working with...

Wearable Devices can Detect COVID-19 Sym…

Wearable devices can identify COVID-19 cases earlier than traditional diagnostic methods and can help track and improve management of the disease, Mount Sinai researchers report in one of the first...

Philips completes the acquisition of Bio…

Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, announced that it has completed the acquisition of BioTelemetry, Inc. (NASDAQ: BEAT), a leading U.S.-based provider of remote...

Siemens Healthineers and Kantonsspital B…

Siemens Healthineers and the Kantonsspital Baden (KSB) in Switzerland, a networked, regional center of competence, have formed a long-term, strategic and technological partnership for the next eight years. This "Value...

A Machine-Learning Approach to Finding T…

When the COVID-19 pandemic struck in early 2020, doctors and researchers rushed to find effective treatments. There was little time to spare. "Making new drugs takes forever," says Caroline Uhler...

Medway Picks Allscripts Sunrise EPR to M…

Medway NHS Foundation Trust is looking to make rapid improvements in its digital maturity with the Allscripts Sunrise electronic patient record. The Kent trust signed a contract with Allscripts in December...

Computational Medicine - Moving from Unc…

Individual choices in medicine carry a certain amount of uncertainty. An innovative partnership at The University of Texas at Austin takes aim at medicine down to the individual level by applying...

26,000 Falls may Have Been Prevented aft…

Greater scrutiny in prescribing amongst elderly patients may have prevented 26,000 falls in a single year, according to new analysis by Kent Surrey Sussex Academic Health Science Network (KSS AHSN). The...

Cybersecurity in Healthcare: HubIT Final…

17 February 2021, Online. The online international workshop "Cybersecurity within Healthcare Systems" takes place on the 17 of February 2021 from 10-13 am CET. The aim of this workshop is to...

Visionable Appoints First CCO Following …

British health technology company Visionable has announced the appointment of David Walker to the newly created position of Chief Commercial Officer (CCO), effective immediately. Visionable redesigns healthcare through a digital...

Researchers Develop Data Tool that may I…

With the aid of sophisticated machine learning, researchers at UPMC and the University of Pittsburgh School of Medicine demonstrated that a tool they developed can rapidly predict mortality for patients...